Milwaukee Journal Sentinel

Thalidomid­e never got FDA approval

- Gabrielle Settles

After the Food and Drug Administra­tion granted full approval to Pfizer’s COVID-19 vaccine for adults Aug. 23, many skeptics of the vaccine have gone on social media to challenge the agency’s safety record and credibilit­y.

“Thalidomid­e was also FDA approved,” says one Facebook post, referring to a drug used more than six decades ago to treat morning sickness. The post includes a picture of four children at a pool who have missing or malformed limbs.

This Aug. 23 post was flagged as part of Facebook’s efforts to combat false news and misinforma­tion on its News Feed.

Thalidomid­e was widely prescribed to pregnant mothers around the world before it was shown to cause thousands of cases of babies born with disabiliti­es, such as missing and malformed limbs.

But the post gets a key fact wrong: The FDA never approved thalidomid­e.

In 1960, FDA medical officer Dr. Frances Oldham Kelsey, reviewing an approval applicatio­n for thalidomid­e from drugmaker Richardson-Merrell, found problems with the company’s claims about its effectiveness.

“The claims were just not supported

by the type of clinical studies that had been submitted in the applicatio­n,” Kelsey said in an autobiogra­phical interview. A transcript of her interviews was provided by the FDA.

Many of the doctors’ reports submitted with the applicatio­n were “more testimonia­ls than scientific studies,” Kelsey said.

She also looked into reports that thalidomid­e’s side effects for adults included painful tingling in the hands and feet. Thousands of babies whose mothers took the drug while pregnant were born

with severe defects to their limbs, internal organs, eyesight and hearing.

Richardson-Merrell withdrew the applicatio­n in 1962. By then, the company and another drugmaker, Smith, Kline & French, had already given about 20,000 Americans thalidomid­e as part of clinical trials – and at least 17 babies were born with disabiliti­es from the drug.

The thalidomid­e case is often held up as a turning point in the FDA’s evaluation of drugs and medical devices. FDA standards are today considered among the world’s strictest, said Dr. Henry Miller, senior fellow at the Pacific Research Institute, former FDA medical reviewer and founding director of the agency’s Office of Biotechnol­ogy.

It was the thalidomid­e case that led the Kennedy administra­tion in 1962 to enact the Kefauver-Harris Amendments, which tightened regulation­s for drug reviews, including a requiremen­t that evidence of a drug’s effectiven­ess be “based on adequate and well-controlled clinical studies conducted by qualified experts.” A 1997 law simplified the process for drug reviews, but the FDA still generally requires results from two well-controlled clinical studies for a drug approval.

The approved Pfizer vaccine and the other vaccines authorized for emergency use were evaluated based on the FDA’s evidence standards.

Even with the stricter standards, the FDA has approved products that were later shown to cause harm, such as breast implants, which were linked to anaplastic large-cell lymphoma, and Vioxx, an anti-inflammatory pain medicine that was pulled from the market after a study showed it raised the risk of heart attacks and strokes.

But thalidomid­e was not one of those products.

Our ruling

A post implicitly questionin­g the FDA’s approval of Pfizer BioNTech’s COVID-19 vaccine said, “Thalidomid­e was also FDA approved.”

The FDA reviewed an applicatio­n for a thalidomid­e drug in the 1960s, but withheld approval amid concerns about the evidence of effectiveness and reports of its side effects. The applicatio­n was withdrawn in 1962.

We rate the claim False.

Newspapers in English

Newspapers from United States